IDT Biologika
Dedicated to Contract Development and Manufacturing of
Viral Vaccines, Viral Vectors and Biologics

IDT Biologika specializes in the contract development and manufacturing of Viral Vaccines, Gene and Immunotherapeutics as well as sterile liquids and lyophilized Biologics. We help biopharmaceutical and biotech companies as well as the US government as part of research consortia with the challenging and complex process of translating viral vaccines and biopharmaceuticals from the research lab through clinical development to large-scale commercial manufacturing including drug substance production, fill & finish, packaging and analytics. IDT Biologika provides fully integrated services for GMP compliant end-to-end services in BSL2 facilities meeting EMA, FDA and ANVISA standards.

We strive for strong, trusting and enduring customer partnerships. Our almost 100 year tradition in manufacturing vaccines and biopharmaceuticals motivates and obligates us to advance our clients’ products to prevent and treat diseases that impact the health of people worldwide.

 

Our Awards

ViE Awards

Best Contract Manufacturing Organization
2021

CMO Leadership Award 2021

Service

CMO Leadership Award 2021

Reliability

PharmaTech Outlook

2020

Twitter
@IDT Biologika

Friday, 30. July 2021

Join us at #CPhI North America and learn how we can support you with our technical and quality expertise in… https://t.co/bXbC6GBFWe more info

Thursday, 15. July 2021

https://t.co/H93zaMXU8G more info

Tuesday, 29. June 2021

Together with the #GermanRedCross - DRK - we have initiated a #blooddonation campaign on our company premises. 42 e… https://t.co/5xZJEViOtc more info

Friday, 18. June 2021

Wer are very proud to announce that #IDT Biologika was awarded a “Highly Commended” status in the category of “Best… https://t.co/MWMC1WGxza more info

Wednesday, 16. June 2021

We are supporting the planting of 8,000 trees. The campaign was initiated by the Club Soroptimist International Des… https://t.co/ejgqOcVik5 more info

Friday, 11. June 2021

Our story continues. See here the next piece of the exciting 100-year-history of #IDT Biologika. We feature 3… https://t.co/we1HjKzw2E more info

Wednesday, 19. May 2021

We are proud to announce that we are now a member of #VaccinesEurope – a voice for the vaccines industry in Europe.… https://t.co/5RTQ0ZVoh2 more info

Wednesday, 5. May 2021

Running well! Our #IDT running team is taking part in the 10-week running challenge organized by the state of… https://t.co/CMP0jcRGUB more info

Wednesday, 21. April 2021

The next article on our 100 year history is now online. We invite you to learn more about research, #development an… https://t.co/JGo6gV87SS more info

Study with optimized vector vaccine MVA-SARS-2-S resumed

Monday, 19. July 2021

Optimized vector vaccine against corona shows good efficacy in preliminary tests. more info

Federal Minister of Health Jens Spahn and Prime Minister Reiner Haseloff visit IDT Biologika

Monday, 19. April 2021

Dessau-based company to now fill AstraZeneca COVID-19 vaccine - Merz Pharma is foregoing capacities at short notice more info

IDT Biologika lays foundations for new multifunctional vaccine production building

Thursday, 8. April 2021

Overall, a total of 100 million euros are currently being invested in the site... more info

IDT Biologika and Takeda support production of the Johnson & Johnson single-shot COVID-19 vaccine

Monday, 15. March 2021

Takeda provides booked capacity at the IDT site in Dessau more info

Start of second study phase of vector vaccine against COVID-19 postponed

Monday, 11. January 2021

Initial data for corona vaccine indicate good tolerability but weak immune response more info